Last reviewed · How we verify

NCT05759052: CIPN-LEA

Vincristine-induced Peripheral Neuropathy in Adult Survivors of Childhood and Adolescent Leukemia

Completed Last updated 24 December 2025
What this trial tests

trial testing self-administered questionnaire in Chemotherapy-induced Peripheral Neuropathy in 467 participants. Completed in 4 November 2025.

Timeline
12 May 2023
Primary endpoint
4 November 2025
4 November 2025

Quick facts

Lead sponsorUniversity Hospital, Clermont-Ferrand
StatusCompleted
Study typeOBSERVATIONAL
Enrollment467
Start date12 May 2023
Primary completion4 November 2025
Estimated completion4 November 2025
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Clermont-Ferrand

Who can join

18 and older, any sex, with Chemotherapy-induced Peripheral Neuropathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Vincristine is a major anticancer agent in the management of hematological malignancies. One of the main side effects is chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a characteristic side effect of neurotoxic anticancer drugs. CIPN associated with vincristine is typically characterized by distal and symmetrical sensory symptoms (dysesthesia and paresthesia). Motor and vegetative symptoms can also be found. The prevalence of CIPN associated with vincristine during treatment ranges from 12 to 100% in children (depending on the endpoint). The aim of this cross-sectionnal study will be to explore the CIPN prevalence and severity in adult survivors of childhood leukemia and having been treated by vincristine.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of self-administered questionnaire

Trials testing the same drug.

Other recruiting trials for Chemotherapy-induced Peripheral Neuropathy

Currently open trials in the same condition.

Other University Hospital, Clermont-Ferrand trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05759052.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing